• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类血栓中纤维蛋白溶解系统的蛋白质。

Proteins of the fibrinolytic system in human thrombi.

作者信息

Robbie L A, Bennett B, Croll A M, Brown P A, Booth N A

机构信息

Department of Medicine and Therapeutics, University of Aberdeen, Scotland, UK.

出版信息

Thromb Haemost. 1996 Jan;75(1):127-33.

PMID:8713791
Abstract

The proteins of fibrinolysis have been quantified in human thrombi, to assess the balance between plasminogen activators and their major inhibitor PAI-1. The relative roles of PAI-1 and alpha 2-AP were also examined since we have previously shown that both platelet PAI-1 and plasma alpha 2-AP are important determinants of clot lysis in vitro. Extracts and sections were prepared from human thrombi for quantitative immunoassay and immunohistochemical staining respectively. PAI-1 and alpha 2-AP were present at high concentrations. Levels of t-PA and t-PA-PAI-1 complex were relatively low. Staining confirmed the presence of abundant PAI-1, associated primarily with platelet material within the thrombus and also with fibrin. Staining for alpha 2-AP was also intense and demonstrated strong association with fibrin. The alpha 2-AP concentration was similar to its high plasma concentration, whereas PAI-1 levels were up to 30 times greater than that in circulating blood, suggesting that active recruitment of platelets contributes to the high PAI-1 concentration in thrombi.

摘要

对人血栓中的纤溶蛋白进行了定量分析,以评估纤溶酶原激活剂与其主要抑制剂PAI-1之间的平衡。由于我们之前已表明血小板PAI-1和血浆α2-抗纤溶酶(α2-AP)都是体外凝块溶解的重要决定因素,因此还研究了PAI-1和α2-AP的相对作用。分别从人血栓制备提取物和切片,用于定量免疫测定和免疫组织化学染色。PAI-1和α2-AP浓度很高。组织型纤溶酶原激活剂(t-PA)和t-PA-PAI-1复合物的水平相对较低。染色证实存在大量PAI-1,主要与血栓内的血小板物质以及纤维蛋白相关。α2-AP染色也很强烈,并显示与纤维蛋白有很强的关联。α2-AP浓度与其高血浆浓度相似,而PAI-1水平比循环血液中的水平高30倍,这表明血小板的活跃募集导致血栓中PAI-1浓度升高。

相似文献

1
Proteins of the fibrinolytic system in human thrombi.人类血栓中纤维蛋白溶解系统的蛋白质。
Thromb Haemost. 1996 Jan;75(1):127-33.
2
The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.α2-抗纤溶酶和纤溶酶原激活物抑制剂1(PAI-1)在抑制血凝块溶解中的作用。
Thromb Haemost. 1993 Aug 2;70(2):301-6.
3
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.体外凝块溶解作为血栓对纤维蛋白溶解抵抗的潜在指标——在健康受试者中的研究及其与血液纤溶参数的相关性
Thromb Haemost. 1997 Apr;77(4):725-9.
4
Demonstration of a functionally active tPA-like plasminogen activator in human platelets.在人血小板中证实存在一种功能活跃的组织型纤溶酶原激活物(tPA)样纤溶酶原激活剂。
Thromb Haemost. 1994 Apr;71(4):493-8.
5
Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.某些骨髓增殖性综合征中的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及纤溶酶原激活剂抑制剂(PAI - 1和PAI - 2)
Med Sci Monit. 2000 Jul-Aug;6(4):684-91.
6
[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].[组织型纤溶酶原激活物及其在前列腺癌手术患者血液中的抑制作用]
Pol Tyg Lek. 1996 Feb;51(6-9):91-3.
7
Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.培养的人系膜细胞可产生1型和2型纤溶酶原激活物抑制剂。
Thromb Haemost. 1995 Dec;74(6):1516-20.
8
Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.纤溶系统各组分在内皮损伤诱导的血栓形成与清除中的不同作用。
Thromb Haemost. 1999 Apr;81(4):601-4.
9
Fibrinolytic activity in peripheral atherosclerosis in the elderly.老年人外周动脉粥样硬化中的纤溶活性。
Thromb Haemost. 1999 Feb;81(2):275-80.
10
Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and RAI-1 content and distribution.
Thromb Haemost. 1997 Mar;77(3):510-5.

引用本文的文献

1
Identification of genomic loci regulating platelet plasminogen activator inhibitor-1 in mice.鉴定调控小鼠血小板纤溶酶原激活物抑制剂-1的基因组位点。
J Thromb Haemost. 2023 Oct;21(10):2917-2928. doi: 10.1016/j.jtha.2023.06.018. Epub 2023 Jun 25.
2
All tangled up: interactions of the fibrinolytic and innate immune systems.错综复杂:纤维蛋白溶解系统与先天免疫系统的相互作用。
Front Med (Lausanne). 2023 Jun 2;10:1212201. doi: 10.3389/fmed.2023.1212201. eCollection 2023.
3
Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications.
纤溶酶原激活系统在血小板病理生理学中的作用:转化应用的新观点。
Int J Mol Sci. 2022 May 28;23(11):6065. doi: 10.3390/ijms23116065.
4
Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi.剪切应力和 tPA 浓度在血栓溶栓潜能中的作用。
Int J Mol Sci. 2021 Feb 20;22(4):2115. doi: 10.3390/ijms22042115.
5
Direct Fibrinolytic Snake Venom Metalloproteinases Affecting Hemostasis: Structural, Biochemical Features and Therapeutic Potential.直接纤溶蛇毒金属蛋白酶对止血的影响:结构、生化特征和治疗潜力。
Toxins (Basel). 2017 Dec 5;9(12):392. doi: 10.3390/toxins9120392.
6
Staphylococcal adaptation to diverse physiologic niches: an overview of transcriptomic and phenotypic changes in different biological environments.葡萄球菌对不同生理生态位的适应:不同生物环境中转录组和表型变化概述
Future Microbiol. 2015;10(12):1981-95. doi: 10.2217/fmb.15.116. Epub 2015 Nov 19.
7
Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".重组组织型纤溶酶原激活剂在体外人血凝块模型中的个体溶解效果:“无反应”率。
Acad Emerg Med. 2013 May;20(5):449-55. doi: 10.1111/acem.12133.
8
The neurovascular unit and combination treatment strategies for stroke.神经血管单位及脑卒中的联合治疗策略。
Trends Pharmacol Sci. 2012 Aug;33(8):415-22. doi: 10.1016/j.tips.2012.04.006. Epub 2012 May 16.
9
Platelets retain high levels of active plasminogen activator inhibitor 1.血小板中保持着高水平的活性纤溶酶原激活物抑制剂 1。
PLoS One. 2011;6(11):e26762. doi: 10.1371/journal.pone.0026762. Epub 2011 Nov 1.
10
Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.在体外人凝块模型中,与 rt-PA 单独治疗相比,联合治疗更有效。
Curr Neurovasc Res. 2011 Nov;8(4):305-12. doi: 10.2174/156720211798120963.